Abstract:A functional monoclonal antibody against human PD-L2(B7-DC,CD273) molecule was prepared and their biological characteristics was analyzed in the present study.The highly expressed human PD-L2 was transfected to L929/PD-L2 cell line and the expressed molecule was used as the immunogen to immunize BALB/c mice.By means of hybridoma cell fusion technique,LD29/PD-L2 cells was used as the target cells,while L929/mock cell was used as the negative control.The hybridoma specifically secreting mouse anti-human PD-L2 monoclonal antibody was generated after indirect fluorescence labeling,flow cytometry(FCM),repeated screening and multiple subcloning.Their biological characterization was investigated by Western blotting,rapid murine Ig subclass typing,indirect immunofluorescene assay,and mutual competitive inhibition test.After multiple fusion and repeated screening,one hybridoma cell line secreting mouse anti-human PD-L2 monoclonal antibody was obtained successfully,and this monoclonal antibody secreted(named as 8F2) could bind to human PD-L2 specially.Through the indirect fluorescence labeling and FCM,it was demonstrated that the PD-L2 molecule was expressed on the mature dendritic cells and regulatory T cells by up-regulation and it could recognize a new epitope on the PD-L2 molecule.By means of the FCM analysis,the expression patterns of PD-L2 on human different cell lines was determined,indicating the increased expression of PD-L2 in mature dendritic cells and activated T cells.From these observations,it is evident that a novel mouse anti-human PD-L2 monoclonal antibody was generated successfully,which recognize different epitopes on PD-L2 and appears to be different to the commercial products.This PD-L2 monoclonal antibody may provide the initial material for further study on the role of human PD-1/PD-L2 signaling pathway in the biological role of immune response.

[Preparation and Characterization of Three Novel Monoclonal Antibodies Against Human PD-L1].

Preparation and characterization of a novel monoclonal antibody against human PD-1

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

[Preparation of Two Mouse Anti-Human PD-1 Monoclonal Antibodies and Identification of Their Biological Characteristics].

Preparation and Characterization of a Novel Monoclonal Antibody Against Human PD-L2 (B7-DC)

Preparation and application of anti-human PD-L1 monoclonal antibodies

[Preparation of a Novel Functional Anti-Human CD40 Monoclonal Antibody and Identification of Its Bioactivity].

Preparation of a Novel Functional Mouse Anti-Human 2Igb7-H3 Antibody and Primary Study of Its Biological Characteristics.

[Preparation and Characterization of a Novel Functional Anti-Human CD83 Monoclonal Antibody].

[Preparation and Characterization of a Mouse Anti-Human CD40 Mutant Monoclonal Antibody].

[Preparation and Characterization of Two Novel Functional Monoclonal Antibodies Against Human OX40L].

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

[Preparation and identification of human soluble sPD-L1 and its antibodies]

Preparation of a functional monoclonal antibody against human 4-1BBL molecule and analysis of its biological characteristics

Development of monoclonal antibodies against PD-L1 and preliminary investigation on potential application in treatment of chronic hepatitis B virus in-fection

Preparation of a novel monoclonal antibody against active components of PHA-L from Phaseolus vulgaris and its functional characteristics

The Preparation of Human Anti-P-Selectin Monoclonal Antibodies

Preparation of Anti-Human 4-1BB Monoclonal Antibody and Analysis of Its Biological Functions

Preparation and Characterization of Monoclonal Antibody Against Human Angiopoietin-Like Protein 2

CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies